| Literature DB >> 24641677 |
Aditya Kulkarni1, Phong Quang, Victoriana Curry, Renee Keyes, Weihong Zhou, Hyejin Cho, Jonathan Baffoe, Béla Török, Kimberly Stieglitz.
Abstract
Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular molecules. Phospholipase D is a target to modulate cancer-cell invasiveness. This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1 . Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the molecules presented here exhibited inhibition of phospholipase D activity (IC50 ) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4 PC and phospholipid vesicles and micelles. The data strongly indicate that these inhibitory molecules directly block enzyme/vesicle substrate binding. Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment.Entities:
Keywords: chemical biology; drug design; protease and ligands (substrate/inhibitor)
Mesh:
Substances:
Year: 2014 PMID: 24641677 DOI: 10.1111/cbdd.12319
Source DB: PubMed Journal: Chem Biol Drug Des ISSN: 1747-0277 Impact factor: 2.817